FIELD: biotechnology and medicine.
SUBSTANCE: invention relates to biotechnology and medicine. The invention is a test system and a method for the differentiated (separate) detection of all classes of specific antibodies to the nucleocapsid and the receptor-binding domain of the spike protein of the coronavirus severe acute respiratory syndrome-2 (SARS-CoV-2) in order to assess the immune response to the transferred or current coronavirus COVID-19 infection, laboratory diagnosis of the current infection in combination with other studies, confirmation of positive or questionable test results, minimization of false positive test results. Includes an immunosorbent based on coronavirus antigens, which are the receptor-binding domain (RBD) and nucleoprotein (N) of the SARS-CoV-2 coronavirus, and detecting reagents, the above antigens are sorbed in different wells of plates for enzyme-linked immunosorbent assay, 96-well collapsible polystyrene tablets.
EFFECT: invention allows determining a standardized relative amount of antibodies to different proteins of the virus due to the standard setting conditions and a single level of the threshold value (cutoff), provides increased sensitivity, simplification and ease of analysis, while in combination with other studies can confirm positive or questionable research results, minimizing false positive results (FPR).
3 cl, 8 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ENZYME IMMUNOASSAY DETERMINATION OF THE LEVEL OF ANTIGEN-RECOGNIZING B-LYMPHOCYTE RECEPTORS REPRESENTED BY MEMBRANE-SPECIFIC RBD PROTEIN SARS-COV-2, IgG ANTIBODIES | 2021 |
|
RU2760438C1 |
| STRAIN OF HCOV-19/RUSSIA/OMSK-202118-1707/2020 OF SARS-COV-2 CORONAVIRUS, IMMUNOSORBENT CONTAINING PURIFIED WHOLE VIRION ANTIGEN OBTAINED ON BASIS OF SPECIFIED STRAIN AND ISA TEST SYSTEM FOR DETECTING ANTIBODIES OF CLASSES M, G AND A TO SARS CORONAVIRUS-COV-2 USING SPECIFIED IMMUNOSORBENT | 2021 |
|
RU2752862C1 |
| METHOD FOR DETERMINING THE ACTIVITY OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2 IN THE SERUM OR PLASMA OF PEOPLE WITH PAST CASES OF COVID-19 OR VACCINATED WITH PREVENTIVE VACCINES AGAINST THE NOVEL CORONAVIRUS INFECTION COVID-19 USING A SET OF ENZYME IMMUNOASSAY REAGENTS CONTAINING A RECOMBINANT RECEPTOR-BINDING DOMAIN (RBD) OF SURFACE GLYCOPROTEIN S OF CORONAVIRUS SARS-CoV-2 AND RECOMBINANT HUMAN RECEPTOR ACE2 | 2021 |
|
RU2784655C1 |
| METHOD OF USING RECOMBINANT PROTEINS SARS-COV-2 AS PART OF A TEST SYSTEM FOR ELISA TEST WITH DETERMINING IGM, IGG, IGA CLASS ANTIBODY LEVELS IN BLOOD SERUM/PLASMA OF COVID-19 PATIENTS | 2020 |
|
RU2730897C1 |
| METHOD FOR DETECTING INFECTION OF HUMANS AND ANIMALS WITH SARS CoV 2 AND A DIAGNOSTIC KIT FOR IMPLEMENTING THE METHOD | 2021 |
|
RU2776295C1 |
| METHOD FOR DETECTING ANTIBODIES - CLASS G IMMUNOGLOBULINS IN BLOOD SERUM TO PATHOGENS OF SEVERE ACUTE RESPIRATORY VIRAL INFECTIONS, INCLUDING SARS-COV-2, WITH SIMULTANEOUS PROGNOSIS OF COVID-19 SEVERITY, BASED ON HYDROGEL BIOCHIP | 2020 |
|
RU2746815C1 |
| THE STRAIN OF HYBRID CULTURED HOMO SAPIENS/Mus MUSCULUS CELLS Hu-C6D7-RBD IS A PRODUCER OF HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE RBD DOMAIN S OF THE SARS-CoV-2 VIRUS PROTEIN | 2022 |
|
RU2788359C1 |
| METHOD FOR QUANTITATIVE DETERMINATION OF CONCENTRATION OF S-ANTIGEN IN WHOLE-VIRION INACTIVATED ADSORBED ON ALUMINUM HYDROXIDE, SUBUNIT BASED ON S-PROTEIN, RECOMBINANT OR POLYPEPTIDE, CONTAINING RBD DOMAIN OF SPIKE PROTEIN OF SARS-COV VIRUS FOR PREVENTION OF CORONAVIRUS INFECTION COVID-19 AND/OR OTHER CORONAVIRUS INFECTIONS | 2023 |
|
RU2825291C1 |
| Method for producing Chinese hamster ovary cell strain, being a producer of recombinant SARS-CoV-2 virus protein RBD, Chinese hamster ovary cell strain, producer of recombinant SARS-CoV-2 protein RBD, method for producing recombinant SARS-CoV-2 virus protein RBD, test system for enzyme immunoassay of human serum or plasma, and use thereof | 2020 |
|
RU2723008C1 |
| MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
